BMI limits [Design Issues]

posted by ElMaestro  – Denmark, 2018-10-31 09:19 (900 d 16:14 ago) – Posting: # 19505
Views: 2,858

Hi Amira Gouda,

» I agree with you, we should strictly follow the study protocol, (NB: protocol BMI range : 18.5 -30 ), but if principal investigator approved this deviation (31.5), recorded in protocol deviation log and submitted to IRB/IEC, what do you think?

On basis of my modest experience situations like this tend to arise out of bad planning when the CRO is running out of eligible subjects close the projected start of the study. That's the time when they start approving all sorts of deviations on BMI, blood sugar, ALAT/ASAT, HB/hematocrit and more in order to be able to meet the enrollment target and stay on time.
You do not ever want to be confronted with questions going in that direction.

What did the PI submit to the IEC/IRB and when exactly?

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 11 (0 registered, 11 guests [including 4 identified bots]).
Forum time: Monday 02:34 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5